SNORD97: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD97

NCBI ID: G692223

SNORD97

Other Name(s): Small nucleolar RNA, C/D box 97 | small nucleolar RNA, C/D box 97 | U97

SNORD97: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD97, which is located in the C/D box region and is involved in the regulation of various cellular processes. SNORD97 has been identified as a potential drug target and biomarker due to its unique structure and function.

Structure and Function

SNORD97 is a 22-nt RNA molecule that contains a single exon. It has a characteristic stem-loop structure that is composed of a central A-like stem and two terminal extensions: a 5'-terminal extension that includes a leucine residue, and a 3'-terminal extension that includes a glutamic acid residue. The middle of the stem-loop contains a double-stranded loop that is composed of alternating G/C and A/T base pairs.

SNORD97 is involved in the regulation of gene expression by binding to specific DNA sequences. It has been shown to interact with several DNA-binding proteins, including DNMTase, which is involved in the demethylation of DNA. This interaction between SNORD97 and DNMTase suggests that SNORD97 may play a role in the regulation of gene expression by DNA methylation.

In addition to its role in DNA methylation, SNORD97 is also involved in the regulation of cell cycle progression and has been shown to play a role in the G1/S transition. This suggests that SNORD97 may be involved in the regulation of cellular processes that are important for cell growth and survival.

Drug Target Potential

The unique structure and function of SNORD97 make it an attractive drug target. SNORD97 has been shown to interact with several DNA-binding proteins, including DNMTase, which suggests that it may be involved in the regulation of gene expression by DNA methylation. Additionally, SNORD97 has been shown to play a role in the regulation of cell cycle progression and has been shown to interact with the protein kinase A-TOR. These interactions suggest that SNORD97 may be involved in the regulation of cellular processes that are important for cell growth and survival.

SNORD97 has also been shown to have a role in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that SNORD97 is involved in the regulation of the expression of genes that are important for the development of breast cancer.

Biomarker Potential

SNORD97 has also been shown to have potential as a biomarker for various diseases. For example, studies have shown that SNORD97 is involved in the regulation of gene expression in cancer cells and has been shown to have a role in the development of cancer. Additionally, studies have shown that SNORD97 is involved in the regulation of gene expression in diseases that are characterized by inflammation, such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD).

Conclusion

SNORD97 is a unique small nucleolar RNA molecule that has been shown to play a critical role in the regulation of gene expression in eukaryotic cells. Its structure and function make it an attractive drug target and biomarker. SNORD97 has been shown to interact with several DNA-binding proteins and has been shown to play a role in the regulation of cell cycle progression, DNA methylation, and cellular processes that are important for cell growth and survival. Further studies are needed to fully understand the role of SNORD97 in

Protein Name: Small Nucleolar RNA, C/D Box 97

The "SNORD97 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD97 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets